RPAM
AKRO

Rhenman & Partners Asset Management’s Akero Therapeutics AKRO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-230,600
Closed -$10.9M – 96
2025
Q3 		$10.9M Buy
230,600
+33,000
+17% +$1.6M 1.21% 33
2025
Q2 		$10.5M Buy
197,600
+105,100
+114% +$4.78M 1.33% 31
2025
Q1 		$3.74M Buy
+92,500
New +$3.92M 0.43% 54

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rhenman & Partners Asset Management's AKRO Position: Q4 2025 in Review

Rhenman & Partners Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 230,600 shares — an estimated $10.9M sold.

Rhenman & Partners Asset Management first reported a position in AKRO in Q1 2025 and held it in 3 quarters. The position peaked at $10.9M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Rhenman & Partners Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 230,600 Akero Therapeutics shares in Q4 2025, an estimated $10.9M.
  • Rhenman & Partners Asset Management first reported a position in Akero Therapeutics in Q1 2025 and held it in 3 quarters.
  • Rhenman & Partners Asset Management's Akero Therapeutics position peaked at $10.9M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.